PUBLISHER: KBV Research | PRODUCT CODE: 1309444
PUBLISHER: KBV Research | PRODUCT CODE: 1309444
North America Fibromyalgia Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Anticonvulsants, Antidepressants, Muscle Relaxants and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030
The North America Fibromyalgia Treatment Market would witness market growth of 3.7% CAGR during the forecast period (2023-2030).
The complexity of fibromyalgia is the reason why diagnosis and treatment are required to take a multifaceted approach, combining medical practitioners from different specialties to address the disease's many symptoms and comorbidities. In addition to several drugs, it may also be treated with dietary and lifestyle changes. The symptoms of fibromyalgia include extreme pain, difficulty sleeping, tiredness, irritability, and memory loss. Fibromyalgia is commonly accompanied by several other symptoms as well. Only three drugs have been approved for use, particularly in treating fibromyalgia, at this time.
Because of this, products that are off-label are utilized more frequently. But increased research and development in pain management is anticipated to support using approved medications for the illness indication. The burden of chronic pain is mostly to blame for the market's expansion. Researchers have found that fibromyalgia changes how the brain and spinal cord process painful and non-painful signals, increasing the intensity of painful sensations. The increased incidence of chronic pain conditions like fibromyalgia is anticipated to increase demand for different treatment alternatives, ultimately fueling market expansion during the anticipated period.
Mexico's road traffic fatalities have remained consistently high in recent years, despite the country's population of nearly 130 million people. There were over 16,000 recorded deaths in 2019. Due to a lack of accountability among various sectors and institutions, Mexico's federal government struggled to achieve intersectoral coordination and progress in road safety, resulting in fatal and non-fatal traffic injuries. The increasing number of road accidents in the region will create growth opportunities for the market as FM can occur to people involved in road accidents, thereby boosting the market expansion in the region.
The US market dominated the North America Fibromyalgia Treatment Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,022.1 million by 2030. The Canada market is poised to grow at a CAGR of 6.1% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 5.1% during (2023 - 2030).
Based on Drug Class, the market is segmented into Anticonvulsants, Antidepressants, Muscle Relaxants and Others. Based on Distribution Channel, the market is segmented into Drug stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments covered in the Report:
By Drug Class
- Anticonvulsants
- Antidepressants
- Muscle Relaxants
- Others
By Distribution Channel
- Drug stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- AbbVie, Inc.
- Novartis AG
- Eli Lilly And Company
- Amneal Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Zydus Lifesciences Ltd.
- Lupin Limited
- Abbott Laboratories
- Viatris, Inc.
- Sun Pharmaceutical Industries Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Fibromyalgia Treatment Market, by Drug Class
- 1.4.2 North America Fibromyalgia Treatment Market, by Distribution Channel
- 1.4.3 North America Fibromyalgia Treatment Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. North America Fibromyalgia Treatment Market by Drug Class
- 3.1 North America Anticonvulsants Market by Country
- 3.2 North America Antidepressants Market by Country
- 3.3 North America Muscle Relaxants Market by Country
- 3.4 North America Others Market by Country
Chapter 4. North America Fibromyalgia Treatment Market by Distribution Channel
- 4.1 North America Drug stores & Retail Pharmacies Market by Country
- 4.2 North America Hospital Pharmacies Market by Country
- 4.3 North America Online Providers Market by Country
Chapter 5. North America Fibromyalgia Treatment Market by Country
- 5.1 US Fibromyalgia Treatment Market
- 5.1.1 US Fibromyalgia Treatment Market by Drug Class
- 5.1.2 US Fibromyalgia Treatment Market by Distribution Channel
- 5.2 Canada Fibromyalgia Treatment Market
- 5.2.1 Canada Fibromyalgia Treatment Market by Drug Class
- 5.2.2 Canada Fibromyalgia Treatment Market by Distribution Channel
- 5.3 Mexico Fibromyalgia Treatment Market
- 5.3.1 Mexico Fibromyalgia Treatment Market by Drug Class
- 5.3.2 Mexico Fibromyalgia Treatment Market by Distribution Channel
- 5.4 Rest of North America Fibromyalgia Treatment Market
- 5.4.1 Rest of North America Fibromyalgia Treatment Market by Drug Class
- 5.4.2 Rest of North America Fibromyalgia Treatment Market by Distribution Channel
Chapter 6. Company Profiles
- 6.1 Abbott Laboratories
- 6.1.1 Company Overview
- 6.1.2 Financial Analysis
- 6.1.3 Segmental and Regional Analysis
- 6.1.4 Research & Development Expense
- 6.1.5 SWOT Analysis
- 6.2 AbbVie, Inc.
- 6.2.1 Company Overview
- 6.2.2 Financial Analysis
- 6.2.3 Regional Analysis
- 6.2.4 Research & Development Expense
- 6.2.5 Recent strategies and developments:
- 6.2.5.1 Acquisition and Mergers:
- 6.3 Novartis AG
- 6.3.1 Company Overview
- 6.3.2 Financial Analysis
- 6.3.3 Segmental and Regional Analysis
- 6.3.4 Research & Development Expense
- 6.3.5 Recent strategies and developments:
- 6.3.5.1 Acquisition and Mergers:
- 6.4 Eli Lilly And Company
- 6.4.1 Company Overview
- 6.4.2 Financial Analysis
- 6.4.3 Regional Analysis
- 6.4.4 Research & Development Expenses
- 6.5 Amneal Pharmaceuticals, Inc.
- 6.5.1 Company Overview
- 6.5.2 Financial Analysis
- 6.5.3 Segmental Analysis
- 6.5.4 Research & Development Expenses
- 6.6 Teva Pharmaceutical Industries Ltd.
- 6.6.1 Company Overview
- 6.6.2 Financial Analysis
- 6.6.3 Regional Analysis
- 6.6.4 Research & Development Expenses
- 6.7 Zydus Lifesciences Ltd.
- 6.7.1 Company Overview
- 6.7.2 Financial Analysis
- 6.7.3 Segmental and Regional Analysis
- 6.7.4 Research & Development Expense
- 6.7.5 Recent strategies and developments:
- 6.7.5.1 Trials and Approvals:
- 6.8 Lupin Limited
- 6.8.1 Company Overview
- 6.8.2 Financial Analysis
- 6.8.3 Recent strategies and developments:
- 6.8.3.1 Trials and Approvals:
- 6.9 Viatris, Inc.
- 6.9.1 Company Overview
- 6.9.2 Financial Analysis
- 6.9.3 Segmental Analysis
- 6.9.4 Research & Development Expense
- 6.10. Sun Pharmaceutical Industries Ltd.
- 6.10.1 Company Overview
- 6.10.2 Financial Analysis
- 6.10.3 Regional Analysis
- 6.10.4 Research & Development Expenses
LIST OF TABLES
- TABLE 1 North America Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 2 North America Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 3 North America Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 4 North America Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 5 North America Anticonvulsants Market by Country, 2019 - 2022, USD Million
- TABLE 6 North America Anticonvulsants Market by Country, 2023 - 2030, USD Million
- TABLE 7 North America Antidepressants Market by Country, 2019 - 2022, USD Million
- TABLE 8 North America Antidepressants Market by Country, 2023 - 2030, USD Million
- TABLE 9 North America Muscle Relaxants Market by Country, 2019 - 2022, USD Million
- TABLE 10 North America Muscle Relaxants Market by Country, 2023 - 2030, USD Million
- TABLE 11 North America Others Market by Country, 2019 - 2022, USD Million
- TABLE 12 North America Others Market by Country, 2023 - 2030, USD Million
- TABLE 13 North America Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 14 North America Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 15 North America Drug stores & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 16 North America Drug stores & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
- TABLE 17 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 18 North America Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
- TABLE 19 North America Online Providers Market by Country, 2019 - 2022, USD Million
- TABLE 20 North America Online Providers Market by Country, 2023 - 2030, USD Million
- TABLE 21 North America Fibromyalgia Treatment Market by Country, 2019 - 2022, USD Million
- TABLE 22 North America Fibromyalgia Treatment Market by Country, 2023 - 2030, USD Million
- TABLE 23 US Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 24 US Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 25 US Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 26 US Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 27 US Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 28 US Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 29 Canada Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 30 Canada Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 31 Canada Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 32 Canada Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 33 Canada Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 34 Canada Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 35 Mexico Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 36 Mexico Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 37 Mexico Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 38 Mexico Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 39 Mexico Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 40 Mexico Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 41 Rest of North America Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 42 Rest of North America Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 43 Rest of North America Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 44 Rest of North America Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 45 Rest of North America Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 46 Rest of North America Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 47 Key Information - Abbott Laboratories
- TABLE 48 Key information - AbbVie, Inc.
- TABLE 49 Key Information - Novartis AG
- TABLE 50 Key Information - Eli Lilly And Company
- TABLE 51 Key Information - Amneal Pharmaceuticals, INc.
- TABLE 52 Key Information - Teva Pharmaceuticals Industries Ltd.
- TABLE 53 Key Information - Zydus Lifesciences Ltd.
- TABLE 54 Key Information - Lupin Limited
- TABLE 55 key information - Viatris, Inc.
- TABLE 56 Key Information - Sun Pharmaceutical Industries Ltd.
List of Figures
- FIG 1 Methodology for the research
- FIG 2 North America Fibromyalgia Treatment Market share by Drug Class, 2022
- FIG 3 North America Fibromyalgia Treatment Market share by Drug Class, 2030
- FIG 4 North America Fibromyalgia Treatment Market by Drug Class, 2019 - 2030, USD Million
- FIG 5 North America Fibromyalgia Treatment Market share by Distribution Channel, 2022
- FIG 6 North America Fibromyalgia Treatment Market share by Distribution Channel, 2030
- FIG 7 North America Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2030, USD Million
- FIG 8 North America Fibromyalgia Treatment Market share by Country, 2022
- FIG 9 North America Fibromyalgia Treatment Market share by Country, 2030
- FIG 10 North America Fibromyalgia Treatment Market by Country, 2019 - 2030, USD Million
- FIG 11 Swot analysis: Abbott laboratories
